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ABSTRACT
Background: To analyze the efficacy and toxicity of bevacizumab on survival 
outcomes in recurrent ovarian cancer.
Results: Bevacizumab was associated with significant improvement of PFS 
and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 − 0.63;  
p < 0.00001) and 0.87 (95% CI, 0.77  to 0.99; p = 0.03), respectively.
Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 
95% CI 7.77 – 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 − 55.25;  
p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 − 19.27; 
p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 – 7.32; p = 0.008).
Materials and Methods: Three randomized phase III trials representing 1502 
patients were identified.
Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence 
interval (CI) were calculated using fixed or random effects model.
Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS 
and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.
INTRODUCTION
The vast majority of patients with primary epithelial 
ovarian cancer (OC) will experience a recurrence of their 
disease despite aggressive primary cytoreduction surgery 
and adjuvant cytotoxic chemotherapy.
Randomized phase III trials of bevacizumab in 
postoperative patients with primary OC have shown an 
improvement in progression free survival (PFS) without 
an appreciable significantly longer overall survival (OS) 
[1–2]. This benefit of bevacizumab incorporation into 
standard chemotherapy was also confirmed in recurrent 
disease after adjuvant platinum-based chemotherapy 
[3–4]. But neither of the two largest trials of bevacizumab 
in addition to standard chemotherapy  in recurrent disease 
showed evidence of OS improvement over chemotherapy 
alone. Recently randomized GOG 213 trial has been 
presented and results have demonstrated improved PFS 
rates, as well as positive trend in OS, with HR 0.829 
(95% CI 0.683 to 1.005, p = 0.056) [5]. However the 
survival benefit must be weighed in light of the acute 
toxicity. Thus we performed an update meta-analysis 
to include all randomized bevacizumab trials to test 
whether bevacizumab regimen in recurrent OC could be 
superior to standard chemotherapy, in term of efficacy 
and toxicity.
RESULTS
Description of patients
The selection of trials is depicted in the flow chart 
(Figure 1). Briefly, 158 articles were identified, of which 
132 were excluded because they did not fulfill inclusion 
criteria. Twenty-six clinical trials were potentially eligible 
but 23 were excluded because they were not randomized 
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phase III clinical trials. In total, 3 randomized phase III 
trials that evaluated bevacizumab plus chemotherapy 
versus chemotherapy alone for the treatment of recurrent 
OC were selected [3–5]. In the OCEANS trial no prior 
chemotherapy in the recurrent setting was allowed, 
whereas in the AURELIA trial and in the GOG 213 trial a 
total of 26 patients (7%) and 67 patients (10%), received 
prior antiangiogenic therapy, respectively. 
Overall survival and progression free survival
The OS analysis was based on 3 trials, 1502 
patients. The HR for OS was 0.87 (95% CI, 0.77  to 
0.99; p = 0.03). There was no evidence of significant 
statistical heterogeneity with an I2 value of 0% (χ2 test 
for heterogeneity, p = 0.61). If we considered the only 
platinum-sensitive population, the HR became 0.88 (95% 
CI, 0.76 − 1.02; p = 0.09). The forest plot of OS is shown 
on Figure 2.
The benefit of bevacizumab on PFS was significant 
(HR 0.53, 95% CI 0.44 − 0.63; p < 0.00001; χ2 test for 
heterogeneity, p =  0.11; I2 = 55%; Figure 3).
Objective response rate
Bevacizumab has a significantly better ORR, with 
OR of 2.74 (95% CI 2.17 – 3.47; p < 0.00001; χ2 test 
for heterogeneity, p = 0.90; I2 = 0%). Details are shown 
in Figure 4.
Toxicity
Among the 8 analyzed toxicities, only grade 
3 to 4 hypertension (RR 19.01, 95% CI 7.77 – 46.55; 
p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 – 
55.25; p < 0.00001), ATE (RR 4.99, 95% CI 1.29 – 19.27; 
p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 – 7.32; 
p = 0.008) were significantly different between the two 
groups, with heterogeneity among trials. Data on the 
ATE were not available for OCEANS trial [3], thus ATE 
toxicity was calculated without those patients.
Details of RR of toxicities associated with 
bevacizumab plus chemotherapy versus chemotherapy 
alone are shown in Figure 5. 
DISCUSSION
This meta-analysis provides an high level of 
evidence regarding the beneficial effect of bevacizumab 
in recurrent OC. The addiction of bevacizumab to standard 
chemotherapy confers a survival benefit, both progression-
free and overall, which is consistent also in platinum-
sensitive patients. 
Actually, the VEGF-neutralizing monoclonal 
antibody bevacizumab has shown activity in OC 
treatment, on both first-line and recurrent setting and it 
has been the first anti-angiogenesis agent to be approved 
for treatment of OC in the front-line setting [1–2]. In the 
recurrent setting, two large randomized clinical trials have 
Figure 1:  Flow-chart of meta-analysis.
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demonstrated the benefit of the addition of bevacizumab 
to a second-line regimen in both platinum sensitive [3] and 
platinum resistant [4] settings. No OS benefit was found, 
in both trials. More recently  the GOG 213 trial [5], found 
that paclitaxel, carboplatin, and bevacizumab extended 
OS in patients with platinum-sensitive recurrent OC, but 
narrowly missed that statistical upper limit of significance. 
The combination was also associated with a significant 
improvement in PFS as well as ORR. 
This meta-analysis consists of OC patients with 
recurrent disease included in randomized trials of 
bevacizumab combined with chemotherapy. In the light 
of the most recent evidences and with the update of each 
trial, it adds significant evidences compared with previous 
published meta-analysis [6–7].
Our analysis showed that the combination of 
bevacizumab with standard treatment of recurrent 
OC is beneficial in prolonging PFS (HR 0.53, 95% CI 
0.44 − 0.63) and assuring an increased response rate 
(OR 2.74, 95% CI 2.17 – 3.47). Unfortunately, we did 
not analyze data concerning QoL as they were lacking 
or not homogeneous. Active treatment is generally 
undertaken with the goals of providing improved 
quantity and/or quality of patient survival. It has been 
demonstrated a strong association between PFS, cancer-
related symptoms, and QoL among patients with cancer 
[8]. Nonetheless, it should be underlined that in both the 
AURELIA trials and in the GOG 213 trial a quality-of-
life assessment showed no deterioration of life quality 
in patients randomized to bevacizumab. Notably, 
Figure 2: Forest plot for overall survival.
Figure 3: Forest plot for progression free survival.
Figure 4: Forest plot for objective response rate.
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Figure 5: Forest plot for toxicity.
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platinum-resistant OC patients form the AURELIA trial 
receiving bevacizumab plus chemotherapy showed 
a response rate of more than 30%, and significant 
prolongation of PFS but also a 15% improvement in 
abdominal and gastrointestinal symptoms, significantly 
greater  than in the chemotherapy group (21.9% versus 
9.3%, 95% CI: 4.4 – 20.9, p = 0.002) [9]. Therefore it 
might be speculate that the adjunct of bevacizumab has 
not any detrimental effect in terms of QoL; conversely, 
it might have a positive effect in those with the greatest 
symptomatology, as the platinum resistant group of patients.
In terms of toxicity, we have analyzed G3/G4 
toxicities as we focused on those toxicities that might 
have been disadvantageous in terms of outcomes and 
QoL. Overall, there were more side effects in the group 
that used bevacizumab-containing regimen but all 
remained within expected parameters and also toxicities 
were all manageable. Interestingly, should be noticed 
that toxicity data from the GOG 213, which included 
approximately 10% of women who had previously 
received bevacizumab,  are in agreement with those 
previously published, with  an higher  occurrence  of 
G3/G4 thromboembolisms, hypertension and proteinuria 
compared with standard arm. As there is an increase in 
toxicity, attention should be given to patients that have an 
increased risk of bleeding, recent or current use of aspirin 
or oral and/or parenteral anticoagulants. Hypertension 
and proteinuria are usually controllable events and do not 
require permanent discontinuation of bevacizumab.
Finally, we also presented data about OS, which 
were not mature when previous meta-analysis have been 
published. The addition of bevacizumab was associated 
with a small but significant improvement in OS (HR:0.87; 
95% CI 0.77 − 0.99). When considering only platinum 
sensitive patients, the analysis points again to a benefit of 
chemotherapy plus bevacizuamb, although in a different 
extent (HR 0.88, 95% CI, 0.76 − 1.02). 
Remarkably, it should be pointed out that AURELIA 
and OCEANS trials were designed and powered to 
evaluate PFS and not OS as primary end-point; conversely, 
GOG 213 trial had OS as  primary end-point and narrowly 
missed the significance (p = 0.056). Nonetheless, when 
it was designed in 2007 the superiority of adding the 
angiogenesis inhibitor was not still proven and therefore 
investigators used two-tailed statistical analysis. But 
currently, as bevacizuamb’s knowledge  has increased, 
it is more common to use a one-tailed test, which would 
have allowed the significance to be reached. Moreover, 
the estimated median OS of control arm was fixed to 
22 months and this underestimation  might have contribute 
to the trial to miss the statistical cut-off.
This trend was found also when considering only 
sensitive disease but without clear significance, suggesting 
that further prospective studies are needed to investigate if 
OS could be improved through bevacizumab plus standard 
chemotherapy in some selected population. 
Furthermore, even if no definitive evaluation of 
the usefulness of bevacizumab beyond chemotherapy 
can be made within the current meta-analysis, should 
be underlined that in all 3 studies, differently from 
randomized studies in the first-line setting in which no 
global OS  benefit was found [1–2], bevacizumab was 
administered as monotherapy until disease progression or 
unacceptable toxicity in those patients who did not progress 
during the protocol of the six cycles of combination. This 
might be of interest in the debate concerning the length 
of administration of this compound, which is the object 
of several trials (BOOST  trial, NCT01462890; MITO16/
MANGO2b trial; NCT01802749) currently ongoing in the 
first line setting.
Our analysis was limited by its use of summary 
data rather than data from the individual patients from 
each trial. Individual patient data are needed to better 
account for the control arm, to standardize the analysis 
to perform an intent-to-treat analysis, to draw survival 
curves, to perform a more complete analysis of the 
variation of treatment effects according to patient. It 
was originally intended that this summary level analysis 
would be followed by an analysis of individual patient 
data from the eligible trials but, ultimately, this has not 
been possible. 
Further trials are needed, which should also 
consider the QoL as well as the cost of bevacizumab 
plus chemotherapy combination in the recurrent setting; 
moreover the next challenge is to identify those biomarkers 
that might allow to better define the subgroup population 
who may benefit at most of this compound.  
MATERIALS AND METHODS
Data collection and trials selection
The Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement 
was followed to perform the meta-analysis. It includes 
randomized clinical trials, written in English, without any 
restrictions on publication date. The last search was done 
on July 2015. Literature electronic databases (Pubmed, 
Medline and Scopus) were searched for “recurrent”, 
“ovarian cancer” and “bevacizumab” in the title. Trials that 
compared bevacizumab plus chemotherapy administration 
to standard chemotherapy alone in women with recurrent 
OC were eligible. To reduce publication bias, data 
from all clinical randomized trials, both published and 
unpublished, were included using literature electronic 
databases searching (Pubmed, Medline and Scopus) 
and hand searching (meeting proceedings of Society of 
Gynecologic Oncology, European Society of Medical 
Oncology and American Society of Clinical Oncology). 
Reference lists of previously published reviews and meta-
analyses were explored. Review articles, case reports, 
commentaries and letters were not included. 
Oncotarget13226www.impactjournals.com/oncotarget
Two independent investigators (CM and FDF) 
selected the identified studies based on the title and 
abstract. If the study’s topic could not be ascertained from 
its title or abstract, the full-text version would be retrieved 
for evaluation. Disagreement was resolved by discussion 
or consensus or with a third party (LM).
Trials were eligible if patients had a proven OC 
recurrence. In the closer evaluation of potentially eligible 
articles, when two articles appeared to report results with 
overlapping data, only the data representing the most 
recent publication date were included in the meta-analysis. 
From all including studies were extracted: first author’s 
last name, publication year, the study name, sample size 
of cases and controls, regimen used, data on PFS, OS, 
objective response rate (ORR) and acute toxicities ≥ G3. 
Update information on survival and date of last follow-up 
were requested.
End-points
End-points were the PFS, defined as the time from 
random assignment to progression disease or death, the 
OS, defined as the time from randomization to death, the 
objective response rate (ORR) and toxicity. The hazard 
ratios (HR) and 95% confidence interval (CI) for PFS and 
OS were derived from each study; whereas for ORR and 
toxicities were derived the odd ratios (OR) and risk ratios 
(RR), respectively. 
The toxicities analyzed were graded > 2 and were 
gastrointestinal (GI), hypertension, proteinuria, venous 
thromboembolic events (VTE), arterial thromboembolic 
events (ATE), bleeding, would healing and neutropenia. 
If the grade ≥ 3 adverse events were not directly provided 
in the text, they were estimated resulting from data in the 
appropriate Figure/Table.
Statistical analysis
Statistical analysis of pooled ORR, PFS, OS and 
toxicities were performed using Review manager 5.0 
software (http://www.cochrane.org). The pooled HR, OR and 
RR were calculated using a fixed or random effect models, 
depending on heterogeneity. Forest plot were used for 
graphical representation of each study and pooled analysis.
The size of every box represents the weight that 
the corresponding study exerts in the meta- analysis; CI 
of each study are displayed as horizontal line through 
the box. The pooled HR, OR and RR are symbolized by 
a solid diamond at the bottom of the forest plot and the 
width of the square represents the 95% CI of HR. 
HR, OR, RR and 95% CI for each study were 
extracted or calculated based on the published studies 
according to the methods described by Tierney in 2007 [10]. 
A significant two-way p-value for comparison was defined 
as p < 0.05. The size of the square represents the weight 
that the corresponding study exerts in the meta-analysis. 
Statistical heterogeneity between studies was examined 
using both the Cochrane Q statistic (significant at p < 0.1) 
and the I2 value (significant heterogeneity if > 50%) [11]. 
Publication bias was examined using analyses described 
by Egger and Begg [12–13]. 
CONCLUSION
This meta-analysis of randomized studies indicates 
that integrate bevacizumab in the standard treatment for 
patients with recurrent OC prolongs PFS and OS, without 
unexpected toxicity patterns.
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